Vella, Laura J <br/><br/>
MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells.  [electronic resource] 

 -  Cancer immunology research  Apr 2014 
 - 351-60 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2326-6074 
<br/><br/><label>Standard No.: </label>10.1158/2326-6066.CIR-13-0181  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antigens, Neoplasm--immunology<br/>Cell Differentiation<br/>Cell Proliferation--drug effects<br/>Cross-Priming--immunology<br/>Cytokines--biosynthesis<br/>Dendritic Cells--cytology<br/>Epitopes, T-Lymphocyte--immunology<br/>Humans<br/>Imidazoles--pharmacology<br/>Lipopolysaccharides--immunology<br/>Lymphocyte Activation--drug effects<br/>Lymphocyte Subsets--drug effects<br/>Lymphocytes--drug effects<br/>Mitogen-Activated Protein Kinase Kinases--antagonists & inhibitors<br/>Oximes--pharmacology<br/>Protein Kinase Inhibitors--pharmacology<br/>Proto-Oncogene Proteins B-raf--antagonists & inhibitors<br/>Pyridones--pharmacology<br/>Pyrimidinones--pharmacology